Target Price | HK$11.93 |
Price | HK$8.52 |
Potential |
40.07%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target Grand Pharmaceutical 2026 .
The average Grand Pharmaceutical target price is HK$11.93.
This is
40.07%
register free of charge
HK$12.60
47.89%
register free of charge
HK$6.26
26.50%
register free of charge
|
|
A rating was issued by 8 analysts: 7 Analysts recommend Grand Pharmaceutical to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Grand Pharmaceutical stock has an average upside potential 2026 of
40.07%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion HK$ | 11.64 | 12.36 |
10.59% | 6.18% | |
EBITDA Margin | 23.39% | 24.91% |
24.25% | 6.52% | |
Net Margin | 21.20% | 16.74% |
18.72% | 21.03% |
5 Analysts have issued a sales forecast Grand Pharmaceutical 2025 . The average Grand Pharmaceutical sales estimate is
This results in the following potential growth metrics:
5 Grand Pharmaceutical Analysts have issued a net profit forecast 2025. The average Grand Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share HK$ | 0.70 | 0.59 |
29.63% | 15.71% | |
P/E | 14.41 | |
EV/Sales | 2.68 |
5 Analysts have issued a Grand Pharmaceutical forecast for earnings per share. The average Grand Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Grand Pharmaceutical...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.